Acute Effects of Hemodiafiltration Versus Conventional Hemodialysis on Endothelial Function and Inflammation

A Randomized Crossover Study

Ping Jia, PhD, Wei Jin, MB, Jie Teng, MD, Hao Zhang, PhD, Jianzhou Zou, MD, Zhonghua Liu, MD, Bo Shen, MB, Xuesen Cao, MD, and Xiaoqiang Ding, MD

Abstract: Endothelial dysfunction and chronic inflammatory process are prevalent in patients with end-stage renal disease (ESRD). The aim of this study was to evaluate the acute and short-term effects of online hemodiafiltration (OL-HDF) versus conventional HD on endothelial function and inflammation.

A prospective, randomized, crossover trial.

Twenty stable ESRD patients undergoing chronic HD treatments were randomly assigned with a 1:1 ratio to conventional HD and to OL-HDF both for 2 weeks (either HD followed by OL-HDF or OL-HDF followed by HD). Markers of endothelial dysfunction such as flow-mediated dilation (FMD) of the brachial artery, soluble endothelial protein C receptor (sEPCR), and soluble thrombomodulin (sTM) were measured at baseline, after the first dialysis session and after 2 weeks. Meanwhile, serum interleukin 6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) levels were measured as well.

Both a single OL-HDF session and 2-week OL-HDF significantly improved brachial FMD% (18.7 ± 6.9% at baseline; 21.5 ± 5.4% after the first dialysis; 21.5 ± 5.7% after 2 weeks; P < 0.05 vs baseline), decreased the levels of sEPCR (from 394.4 [297.9–457.0] ng/ml at baseline to 234.7 [174.1–345.5] ng/ml after the first dialysis, and to 191.5 [138.2–255.0] ng/ml after 2 weeks; P < 0.01 vs baseline) and sTM. In contrast, HD did not change FMD%, even increased the levels of sEPCR and sTM. A reduction in IL-6 level was observed in OL-HDF patients after 2-week dialysis, while IL-6 did not change in HD patients. There was no significant difference in change of hs-CRP level between the OL-HDF and HD treatments.

OL-HDF has both acute and short-term beneficial effects on endothelial dysfunction compared to conventional HD.

INTRODUCTION

There is an increased incidence and worsening of atherosclerosis in patients on maintenance hemodialysis (HD), which may contribute to the high risk of cardiovascular morbidity and mortality. As an early initiating event in atherosclerosis, endothelial dysfunction is almost universal in patients with end-stage renal disease (ESRD). It is probably caused by uremic toxin retention, inflammation, oxidative stress, and the increased fluid shear stress during dialysis sessions. Various endothelial dysfunction markers and methods have been described, such as brachial flow-mediated dilation (FMD), high-sensitive C-reactive protein (hs-CRP), circulating endothelial cells and progenitor cells. Moreover, thrombomodulin (TM), a transmembrane cofactor of the endothelial cells, and endothelial protein C receptor (EPCR), an important regulator of the protein C anticoagulant pathway, which are abundantly produced by endothelial cells during injury, have been defined as new markers of endothelial dysfunction in many disease. The soluble forms of these 2 markers significantly increased in patients on chronic HD. In addition, various proinflammatory cytokines are markedly increased in HD patients, and micro-inflammation induces endothelial cell injury. It appears that HD may induce endothelial dysfunction and chronic HD treatment could predispose patients to vascular disorders.

Conventional HD uses diffusion, the removal of solutes and water across a semipermeable membrane down a concentration gradient, which provides diffusive clearance of low-molecular-weight solutes with limited ability to remove middle-sized solutes. While, hemodiafiltration (HDF) is a combination of convective and diffusive processes for solute removal. Several studies have suggested that HDF are associated with better removal of both small and middle molecules, such as β₂-microglobulin (β₂-MG), more advantageous effects on hemodynamic stability, improved survival, when compared with conventional HD. In addition, long-term online hemodiafiltration (OL-HDF) with ultrapure dialysate seems to reduce inflammatory activity over time compared to HD. Bellien et al also showed that prolonged HDF significantly improved FMD,
decreased blood TNF-α mRNA expression in ESRD patients. However, no studies have evaluated the acute effects of OL-HDF on endothelial dysfunction and inflammation in maintenance HD patients. The aim of this study is to assess whether a single or short-term OL-HDF sessions would ameliorate endothelial dysfunction and inflammation compared with conventional HD in these patients.

METHODS

Study Design and Patients

This was a randomized, single-blinded, crossover trial designed to compare the acute and short effects of OL-HDF versus conventional HD on endothelial dysfunction and inflammation. All enrolled patients were randomly assigned by concealed allocation with a 1:1 ratio to conventional HD and to OL-HDF both for 2 weeks (thrice a week, either HD followed by OL-HDF or OL-HDF followed by HD). Patients were blinded to treatment order. The study adhered to the Declaration of Helsinki and was approved by the Ethical Committee of Fudan University. All participants provided written informed consent.

Participant flow is shown in Figure 1. Potential participants were screened prospectively using consecutive sampling. Of 185 ESRD patients, who initiated routine HD treatment in Zhongshan Hospital from February 2011 to December 2012, 65 potential patients met the initial inclusion criteria: aged 18 to 80 years, arteriovenous (AV) fistula as vascular access, low-flux HD thrice a week, absence of following ill conditions: diabetes mellitus, liver disease, amyloidosis, vasculitis, severe hyperlipopidemia, and cancer. After 6 months of HD treatment, 20 patients were enrolled into the study on the basis of the final inclusion and exclusion criteria. Inclusion criteria included patients being on low-flux HD thrice a week for 6 months, with well-functioning native AV fistulas for blood access, hemoglobin level ranging between 10 and 13 g/dL in the previous 3 months, stable with a minimum dialysis single-pool Kt/V for urea ≥1.2. Exclusion criteria included any acute illness such as infection or cardiovascular event (i.e., acute myocardial infarction) or cerebrovascular (i.e., ischemic stroke) event within the past month, severe hypertension (systolic blood pressure >180 or diastolic blood pressure >110 mm Hg), current estrogen/hormone replacement therapy or intravenous iron therapy or oral antiplatelet drugs (such as aspirin, etc.), life expectancy <3 months because of nonrenal disease. All participants underwent a thorough physical examination with documentation of medical history and medications before study.

Dialysis Protocol

All participants received thrice-weekly dialysis. They were performed with ultrapure dialysis fluids, defined as <0.1 colony-forming units/ml and <0.03 endotoxin units/ml. 1.4 m² low-flux polyethersulfone dialyzers (BLS514SD; Sorin Group Italia, Mirandola, Italy) were used for conventional HD. 1.6 m² high-flux polyethersulfone hemodiafilters (BLS816SD; Bellco, Italia) were used for OL-HDF. OL-HDF was performed in the postdilution mode, with substitution flow 70 to 80 mL/min, and the total substitution volume 12 to 19 L. Blood flow and dialysate flow rates were set at 250 to 300 mL/min and 600 mL/min respectively, and dialysis time was 240 minutes in all study sessions.

Blood Sampling and Laboratory Measurements

On the first and the last day of each treatment (OL-HDF, conventional HD), blood samples were obtained from the arterial port of the vascular access immediately before the onset of dialysis and again at 240 minutes during the dialysis sessions. Plasma and serum were collected respectively, for biochemical parameters and other assays. Samples were aliquoted and stored at −80 °C before assay.

As inflammatory markers, hs-CRP was measured by a modification of the laser nephelometric technique (Behring Diagnostics, GmbH, Marburg, Germany), and interleukin 6 (IL-6) was measured by enzyme-linked immunosorbent assay (ELISA) using commercially available kits (R&D Systems, Minneapolis, MN).

Determination of Endothelial Function and Markers of Endothelial Injury

With high-resolution ultrasonography, endothelial function was determined noninvasively as the percentage of
flow-mediated dilatation (FMD%) of the brachial artery in the nonfistula arm, which was described previously. In brief, brachial artery internal diameter was measured at end-diastole. After basal diameter was recorded, an arterial occlusion cuff was inflated to 200 mm Hg for 5 minutes to create forearm ischemia, and subsequently, deflated to allow reactive hyperemia. Brachial arterial diameter was measured 60 seconds after deflation. FMD was calculated as the percentage change in artery diameter after cuff deflation and the peak diameter after cuff deflation. After return to the baseline value, brachial artery nitroglycerin-mediated dilation (NMD) was assessed by measuring changes in artery diameter after sublingual nitroglycerin administration (0.5 mg). FMD% and NMD% were measured before and after the first dialysis session, as well as after the last dialysis session.

As markers of endothelial cell injury, soluble endothelial protein C receptor (sEPCR) and soluble thrombomodulin (sTM) levels in plasma were evaluated using ELISA kits (Quantikine® Human EPCR Immunoassay and Quantikine® Human Thrombomodulin/BDCA-3 Immunoassay; R&D Systems), according to manufacturer’s instructions.

**Statistical Analyses**

Data were expressed as mean ± standard deviation (SD), median (interquartile range), or percentage, when appropriate. Levels of FMD%, sEPCR, sTM, IL-6, and hs-CRP within OL-HDF and HD patients at each study visit (first dialysis session and 2-week dialysis session) were compared with baseline using paired t tests for normally distributed and signed rank test for skewed parameters. Between-group comparisons (patients characteristics at baseline in HD-then-OL-HDF group vs OL-HDF-then-HD group) were analyzed using t tests for continuous variables or χ² tests for dichotomous variables.

The differences in change in FMD%, sEPCR, sTM, IL-6, and hs-CRP levels from baseline to first dialysis session and to 2 weeks between the 2 treatment modalities were evaluated using a linear regression model. The natural logarithms (Ln) of sEPCR, sTM, IL-6, and hs-CRP (LnsEPCR, LnsTM, LnIL-6, and Lns-CRP) were used for the analyses to improve the fit of the model. A 2-sided P < 0.05 was considered statistically significant. Statistical analyses were performed with SPSS 16.0 (SPSS, Inc., Chicago, IL).

**RESULTS**

**Patients**

A total of 20 participants completed the study (Figure 1). The baseline characteristics and laboratory data of patients included are listed in Table 1. Thirteen of the 20 patients were men. Mean age was 49.2 ± 13.3 years (mean ± standard deviation). Primary diagnoses of ESRD were: primary glomerulonephritis (n = 9), hypertension (n = 3), cystic kidney disease (n = 2), obstructive nephropathy (n = 2), chronic pyelonephritis (n = 1), unknown (n = 3). Antihypertension drugs were used in 18 patients: calcium channel blockers (n = 12), angiotensin converting enzyme (ACE) inhibitors (n = 8), and angiotensin receptor blockers (n = 5), β-blockers (n = 7), α-blockers (n = 7). In addition, erythropoietin was used in 17 patients, and their prescription was unaltered during the whole study. Overall, baseline characteristics and biochemistry were well balanced between the randomizing subgroups (HD-then-OL-HDF and OL-HDF-then-HD).

**Effects of OL-HDF Versus Conventional HD on Endothelial Function**

The flow-mediated dilatation (FMD%) of the brachial artery increased after the first dialysis session, as well as after 2-week dialysis, in patients on OL-HDF treatment (baseline, 18.7 ± 6.9%; first dialysis, 21.5 ± 5.4%; 2-week dialysis, 21.5 ± 5.7%; P < 0.05 vs baseline). While, patients on conventional HD did not show an improvement in FMD% during the corresponding dialysis sessions (baseline, 17.8 ± 6.3; first dialysis, 18.6 ± 7.3%; 2-week dialysis, 17.4 ± 8.9%). The difference in change in FMD% from baseline to 2 weeks between the 2 treatment modalities was statistically significant (P < 0.01; Table 2).

We also evaluated the markers of endothelial cell injury, sEPCR and sTM, during the 2 treatments (Table 3). sEPCR concentration markedly decreased from 394.4 (297.9–457.0) ng/ml at baseline to 234.7 (174.1–345.5) ng/ml after the first dialysis, and to 191.5 (138.2–255.0) ng/ml after 2 weeks in OL-HDF patients (P < 0.01 vs baseline), while slightly increased from 350.0 (285.2–464.0) ng/ml at baseline to 411.8 (320.5–516.3) ng/ml after the first dialysis and to 443.6 (327.9–625.5) ng/ml after 2 weeks in conventional HD patients, with the difference of change between the 2 treatment groups being statistically significant (P < 0.01). A similar trend was found for sTM (Table 2).

**Effects on Inflammation**

A reduction in plasma IL-6 level was observed in OL-HDF patients after 2-week dialysis sessions (3.41 [0.94–9.54] pg/ml vs 5.60 [2.40–12.95] pg/ml at baseline; P < 0.05), while, in HD patients, the IL-6 level did not change significantly (Table 3). From a linear regression analysis, OL-HDF seemed to decrease the IL-6 level during 2-week dialysis sessions when compared to conventional HD treatment (P < 0.01). In addition, patients on HD showed a significant increase in hs-CRP level after a single dialysis session, as well as after 2-week dialysis (baseline, 1.35 (0.50–4.23) mg/L; first dialysis, 1.60 (0.63–5.00) mg/L; 2-week dialysis, 3.70 (0.83–8.02) mg/L; P < 0.05 vs baseline). Hs-CRP level in OL-HDF patients remained relatively stable after 2-week dialysis sessions (baseline, 2.05 (0.60–5.55) mg/L; 2-week dialysis, 1.90 (0.90–10.40) mg/L; P > 0.05). While, there were no significant differences in change of hs-CRP level between the HD patients and OL-HDF patients (P = 0.16).

**DISCUSSION**

Endothelial dysfunction is common in ESRD, linked to a variety of disease states, including atherosclerosis, diabetes mellitus, coronary artery disease, and hypertension. As a marker of endothelial function, brachial FMD in HD patients were lower than healthy population. Both sEPCR and sTM, considered as markers of endothelial cell injury, significantly increased during HD procedures. In this randomized crossover study, we demonstrated that a single OL-HDF session or 2-week OL-HDF could significantly improve brachial FMD%, decreased the levels of sEPCR and sTM in maintenance HD patients as compared with conventional HD. It seemed to suggest that short-term OL-HDF might reduce endothelial cell injury and improve endothelial function.

Several studies indicated the advantageous effects of HDF, Hemodiafiltration may provide hemodynamic and survival benefits above low- and high-flux haemodialysis. Maduell et al evaluated the effects of OL-HDF versus HD on
all-cause mortality and cardiovascular events in chronic HD patients, and found patients who switched to high-efficiency postdilution OL-HDF had a 30% lower risk of all-cause mortality and a 33% lower risk of cardiovascular mortality during 36-month follow-up, as compared with patients who continued on HD. Recently, Bellien et al\textsuperscript{5} also demonstrated that high-efficiency OL-HDF decreased uremic toxins and vascular inflammation in chronic HD patients, and was associated with subsequent improvement in endothelial NO-synthase (eNOS) functionality which played a pivotal role in maintaining the integrity of endothelial cells and endothelial function.\textsuperscript{20}

Systemic inflammation is commonly observed in patients with ESRD.\textsuperscript{21,22} Most circulating acute-phase proteins and proinflammatory cytokines are increased in HD patients when compared with healthy controls,\textsuperscript{23} and higher levels of these factors are associated with high risk of cardiovascular events and mortality.\textsuperscript{24–26} Previous studies indicated the intradialysis course of CRP levels during HD, yielding different results, with some studies reporting no change,\textsuperscript{27,28} whereas some reporting an increase.\textsuperscript{29} den Hoedt et al\textsuperscript{15} reported CRP and IL-6 concentrations increased in patients treated with HD, and remained stable in patients treated with hemodiafiltration, and proposed that long-term hemodiafiltration with ultrapure dialysate might reduce inflammatory activity over time. In this study, we observed an increase in hs-CRP level after a single and short-term HD sessions, however, in OL-HDF patients, the level of hs-CRP remained relatively stable after 2-week dialysis. In addition, we also found a decrease in IL-6 level in OL-HDF patients, while no change in HD patients, after 2-week dialysis sessions. These data seemed to suggest a beneficial effect of short-term OL-HDF in amelioration of inflammation. To our knowledge, this study is the first to evaluate the acute effect of OL-HDF on endothelial function in chronic HD patients. However, there were several limitations. First, our study population was relatively small. We performed a randomized crossover design to increase the power of the study. Second, it was still unclear as to whether acute changes in inflammatory activity could reduce inflammatory activity over time. In this study, we assessed. Inrig et al\textsuperscript{30} found a carryover effect in a randomized crossover trial testing the effect of low versus high dialysate sodium on patients during HD. Likewise, a carryover effect

### TABLE 1. Baseline Characteristics of Participants

|                       | All Participants (n = 20) | HD-Then-OL-HDF (n = 10) | OL-HDF-Then-HD (n = 10) |
|-----------------------|--------------------------|-------------------------|-------------------------|
| Male sex              | 13 (65)                  | 7 (70)                  | 6 (60)                  |
| Age, y                | 49.2 ± 13.3              | 50.2 ± 10.9             | 48.1 ± 15.8             |
| Body mass index, kg/m\(^2\) | 21.4 ± 3.4              | 21.6 ± 4.4             | 21.3 ± 2.2             |
| Systolic blood pressure, mm Hg | 134.1 ± 11.0       | 134.6 ± 12.7           | 133.6 ± 9.8            |
| Diastolic blood pressure, mm Hg | 83.0 ± 9.9            | 81.4 ± 10.0            | 82.4 ± 10.8            |
| Laboratory parameters |                         |                         |                         |
| Albumin, g/dl         | 41.4 ± 2.6               | 40.3 ± 2.3              | 42.4 ± 2.7             |
| ALT, U/L              | 12.3 ± 6.0               | 10.7 ± 5.1              | 13.9 ± 6.6             |
| AST, U/L              | 14.2 ± 5.0               | 13.2 ± 3.0              | 15.2 ± 6.5             |
| FBG, mmol/L           | 4.9 ± 0.5                | 5.0 ± 0.5               | 4.9 ± 0.5              |
| Total cholesterol, mmol/L | 4.6 ± 0.9                | 4.4 ± 0.8               | 4.9 ± 0.9              |
| Triglyceride, mmol/L  | 1.6 ± 0.9                | 1.5 ± 1.0               | 1.8 ± 0.8              |
| HDL-ch, mmol/L        | 1.1 ± 0.4                | 1.1 ± 0.4               | 1.1 ± 0.4              |
| LDL-ch, mmol/L        | 2.8 ± 0.7                | 2.6 ± 0.7               | 2.7 ± 0.7              |
| Serum creatinine, mg/dl | 13.3 ± 3.1               | 12.1 ± 2.6              | 14.6 ± 3.2             |
| Blood urea nitrogen, mg/dl | 89.4 ± 22.4            | 84.4 ± 24.4            | 94.4 ± 20.4            |
| Parathyroid hormone, pg/ml | 368.1 ± 121.1         | 385.4 ± 130.0          | 350.9 ± 115.7          |
| Serum phosphorus, mg/dl | 7.7 ± 1.9                | 7.8 ± 2.2               | 7.7 ± 1.5              |
| Serum calcium, mg/dl  | 9.4 ± 0.8                | 9.3 ± 1.2               | 9.6 ± 0.8              |
| Hemoglobin, g/dl      | 11.2 ± 1.2               | 11.0 ± 0.8              | 11.4 ± 1.5             |
| Single-pool Kt/V      | 1.3 ± 0.2                | 1.3 ± 0.2               | 1.3 ± 0.2              |
| Antihypertension medications |                     |                         |                         |
| Either ACEI or ARB or both | 10 (50)                | 4 (40)                  | 6 (60)                  |
| Calcium channel blocker | 14 (70)                  | 6 (60)                  | 8 (80)                  |
| β-blocker             | 7 (35)                   | 2 (20)                  | 5 (50)                  |
| α-blocker             | 7 (35)                   | 4 (40)                  | 3 (30)                  |
| Other medications     |                         |                         |                         |
| EPO                   | 17 (85)                  | 8 (80)                  | 9 (90)                  |
| EPO dose, U/wk        | 5500 (3000–10000)        | 5000 (3000–10000)       | 6000 (4500–10000)       |

Data for categorical variables are given as number (percentage); data for continuous variables are given as mean ± standard deviation or median (interquartile range).

ACEI = angiotensin-converting enzyme inhibitor, ALT = alanine aminotransferase, ARB = angiotensin receptor blocker, AST = aspartate aminotransferase, BMI = body mass index, DBP = diastolic blood pressure, EPO = erythropoietin, FBG = fasting blood-glucose, HD = hemodialysis, HDL-ch = high-density lipoprotein cholesterol, LDL-ch = low-density lipoprotein cholesterol, OL-HDF = online hemodiafiltration, SBP = systolic blood pressure.
|                  | Baseline  | First Dialysis | 2-Week Dialysis | Change in First dialysis vs Baseline | Change in 2-Week Dialysis vs Baseline | P-value OL-HDF vs HD |
|------------------|-----------|----------------|-----------------|--------------------------------------|---------------------------------------|----------------------|
| FMD (%)          |           |                |                 |                                      |                                       | 0.02                 |
| HD               | 17.8 ± 6.3| 18.6 ± 7.3     | 17.4 ± 8.9      | 0.7 ± 5.1                            | -0.4 ± 8.7                           |                      |
| OL-HDF           | 18.7 ± 6.9| 21.5 ± 5.4     | 21.5 ± 5.7      | 2.8 ± 4.7*                           | 2.8 ± 4.9*                           |                      |
| Difference OL-HDF vs HD | 0.9 ± 6.0 | 3.0 ± 6.2      | 4.1 ± 6.2       |                                      |                                       | 0.44                 |
| NMD (%)          |           |                |                 |                                      |                                       |                      |
| HD               | 16.9 ± 7.0| 17.0 ± 7.2     | 16.1 ± 6.0      | 0.2 ± 2.5                            | -0.8 ± 4.3                           |                      |
| OL-HDF           | 16.5 ± 6.4| 17.2 ± 5.6     | 17.6 ± 7.1      | 0.7 ± 3.5                            | 1.1 ± 4.6                            |                      |
| Difference OL-HDF vs HD | -0.4 ± 4.1 | 0.2 ± 4.5      | 1.5 ± 5.0       |                                      |                                       |                      |
| sEPCR (ng/ml)    |           |                |                 |                                      |                                       | < 0.001              |
| HD               | 350.0 (285.2 to 464.0) | 411.8 (320.5 to 516.3) | 443.6 (327.9 to 625.5) | 11.5 (−39.1 to 88.7) | 47.7 (−20.2 to 147.6)* |                      |
| OL-HDF           | 394.4 (297.9 to 457.0) | 234.7 (174.1 to 345.5) | 191.5 (138.2 to 255.0) | -122.9 (−225.1 to 88.0)** | -200.8 (−281.4 to 118.9)** |                      |
| Difference OL-HDF vs HD | 7.0 (−38.0 to 56.7) | -146.1 (−213.7 to 83.5) | -235.2 (−300.2 to 151.4) |                                      |                                       | < 0.001              |
| sTM (ng/ml)      |           |                |                 |                                      |                                       |                      |
| HD               | 25.9 (20.7 to 28.7) | 29.6 (24.4 to 35.1) | 32.0 (24.9 to 37.4) | 6.9 (1.5 to 9.7)**                  | 6.8 (1.0 to 10.0)**                  |                      |
| OL-HDF           | 26.1 (20.7 to 28.4) | 24.5 (20.4 to 27.0) | 21.5 (17.7 to 28.5) | -1.0 (−2.4 to 2.4)                  | -1.5 (−5.5 to 11.0)*                  |                      |
| Difference OL-HDF vs HD | -0.6 (−3.8 to 3.0) | -5.3 (−9.2 to 1.7) | -8.9 (−14.0 to 3.3) |                                      |                                       |                      |

Values expressed as mean ± standard deviation or median (interquartile range).
P-value OL-HDF versus HD from a linear regression model.
FMD = flow-mediated dilatation, HD = hemodialysis, NMD = nitroglycerin-mediated dilatation, OL-HDF = online hemodiafiltration, sEPCR = soluble endothelial protein C receptor, sTM = soluble thrombomodulin.

*P < 0.05.
**P < 0.01.
TABLE 3. Effects of HD Versus OL-HDF on Inflammation

| 2-Week Dialysis Change in First Dialysis Change in 2-Week Dialysis | P-value OL-HDF vs HD | P-value HD vs Baseline |
|---|---|---|
| IL-6 (pg/ml) | | |
| Baseline | 6.87 (4.56 to 11.53) | 6.14 (2.66 to 15.65) | 4.97 (2.89 to 8.33) | 0.01 |
| OL-HDF vs HD | 0.06 (0.30 to 0.90) | 0.30 (0.03 to 0.75) | 0.20 (0.00 to 0.45) | 0.16 |
| hs-CRP (mg/L) | | |
| Baseline | 1.35 (0.50 to 3.63) | 1.60 (0.63 to 5.73) | 1.60 (0.63 to 5.73) | 0.55 |
| OL-HDF vs HD | 0.15 (0.04 to 0.48) | 0.20 (0.00 to 0.45) | 0.20 (0.00 to 0.45) | 0.20 |

Values expressed as mean ± standard deviation or median (interquartile range).

OL-HDF has acute and short-term beneficial effects on endothelial dysfunction in ESRD patients compared to conventional HD, which may be related to the amelioration of inflammation, better removal of middle molecular weight substances. We could speculate a superior effect of OL-HDF in the case of its application to the chronic HD patients, especially with high risk of cardiovascular complications. Further studies are required to assess the possible therapeutic effects of the intermittent OL-HDF on endothelial dysfunction and chronic inflammation that are associated with HD.

CONCLUSION

OL-HDF has acute and short-term beneficial effects on endothelial dysfunction in ESRD patients compared to conventional HD, which may be related to the amelioration of inflammation, better removal of middle molecular weight substances. We could speculate a superior effect of OL-HDF in the case of its application to the chronic HD patients, especially with high risk of cardiovascular complications. Further studies are required to assess the possible therapeutic effects of the intermittent OL-HDF on endothelial dysfunction and chronic inflammation that are associated with HD.

ACKNOWLEDGMENT

The authors thank all participating patients and the dialysis nurses participating in this project.

REFERENCES

1. Dursun B, Dursun E, Suleymanlar G, et al. Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol Dial Transplant. 2008;23:1697–1703.
2. Malyzko JS, Malyzko J, Hrysztok T, et al. Markers of endothelial damage in patients on hemodialysis and hemodiafiltration. J Nephrol. 2006;19:150–154.
3. Ramirez R, Carracedo J, Merino A, et al. Microinflammation induces endothelial damage in hemodialysis patients: the role of convective transport. Kidney Int. 2007;72:108–113.
4. Yildiz A, Oflah H, Pusaroglu H, et al. Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients. Am J Kidney Dis. 2003;41:616–623.
5. Bellien J, Fréguin-Bouilland C, Joannides R, et al. High-efficiency on-line haemodiafiltration improves conduit artery endothelial function compared with high-flux haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant. 2014;29:414–422.
6. Kurosawa S, Stearns-Kurosawa DH, Hidari N, et al. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest. 1997;100:411–418.
7. Sescin C, Yin X, Esmon CT, et al. Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence. Kidney Int. 2005;68:110–120.
8. Keven K, Elmali S, Sule Sengul S, et al. Soluble endothelial cell protein C receptor and thrombomodulin levels after renal transplantation. Int Urol Nephrol. 2010;42:1093–1098.
9. Leyholdt JK. Solute flows in different treatment modalities. Nephrol Dial Transplant. 2000;15(Suppl. 1):3–9.
10. Wizemann V, Kulz M, Techert F, et al. Efficacy of haemodiafiltration. Nephrol Dial Transplant. 2001;16(Suppl. 4):27–30.
11. Penne EL, van der Weerd NC, Blankenstijn PJ, et al. Role of residual kidney function and convective volume on change in β2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol. 2010;5:80–86.
12. Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol. 2010;21:1798–1807.
13. Canaud B, Bragg-Gresham JL, Marshall MR. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. *Kidney Int.* 2006;69:2087–2093.

14. Maduell F, Moreo F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduced allcause mortality in hemodialysis patients. *J Am Soc Nephrol.* 2013:24487–24497.

15. den Hoedt CH, Bots ML, Muriel PC, et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. *Kidney Int.* 2014;86:423–432.

16. Liao JK. Linking endothelial dysfunction with endothelial cell activation. *J Clin Invest.* 2013;123:540–541.

17. Kaya Y, Ari E, Halit Demir H, et al. Accelerated atherosclerosis in haemodialysis patients; correlation of endothelial function with oxidative DNA damage. *Nephrol Dial Transplant.* 2012;27:1164–1169.

18. Ronco C. Hemodiafiltration: evolution of a technique towards better dialysis care. *Contrib Nephrol.* 2011;168:19–27.

19. Vilar E, Farrington K. Haemodialysis. *Medicine.* 2011;39:429–433.

20. Nakagawa T, Tanabe K, Croker Bp, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. *Nat Rev Nephrol.* 2011;7:36–44.

21. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease—what have we learned in 10 years? *Semin Dial.* 2010;23:498–509.

22. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? *J Am Soc Nephrol.* 2006;17(12 Suppl. 3):S169–S173.

23. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. *Kidney Int.* 1998;54:236–244.

24. Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? *Clin J Am Soc Nephrol.* 2008;3:505–521.

25. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. *Am J Kidney Dis.* 2001;38:1343–1350.

26. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. *Kidney Int.* 2005;67:1216–1233.

27. Yamamoto T, Nascimento MM, Hayashi SY, et al. Changes in circulating biomarkers during a single hemodialysis session. *Hemodial Int.* 2012;17:59–66.

28. Meuwese CL, Halbesma N, Stenvinkel P, et al. Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. *Nephrol Dial Transplant.* 2010;25:3717–3723.

29. Korevaar JC, van Manen JG, Dekker FW, et al. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. *J Am Soc Nephrol.* 2004;15:2916–2922.

30. Inrig JK, Molina C, D’Silva K, et al. Effect of low versus high dialysate sodium concentration on blood pressure and endothelial-derived vasoactivators during hemodialysis: a randomized crossover study. *Am J Kidney Dis.* 2015;65:464–473.